GDC-0810

DRUG3 trials

Sponsors

Genentech, Inc.

Conditions

Breast Cancer

Phase 1

A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

TerminatedNCT01823835

Genentech, Inc.Breast Cancer

Start: 2014-12-29End: 2020-03-13Updated: 2021-06-18

Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential

CompletedNCT02621957

Genentech, Inc.Breast Cancer

Start: 2015-12-31End: 2016-02-29Updated: 2016-11-02

Phase 2

A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy

TerminatedNCT02569801

Genentech, Inc.Breast Cancer

Start: 2015-12-04End: 2020-02-28Updated: 2021-04-23

Related Papers

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer

Breast Cancer Research and Treatment2022-11-1920 citations

Abstract CT231: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with estrogen receptor+ HER2-, advanced/metastatic breast cancer

Cancer Research2015-08-0124 citations

Abstract OT3-2-07: Phase I study of ARN-810, a novel selective estrogen receptor degrader, in post-menopausal women with locally advanced or metastatic estrogen receptor positive breast cancer

Cancer Research2013-12-1511 citations